Following an abbreviated submission, the Scottish Medicines Consortium (SMC) has accepted calcium acetate (PhosLo®) for use in NHS Scotland for prevention/treatment of hyperphosphataemia in patients with advanced renal failure on dialysis.

The drug advice notes that for patients in whom calcium acetate is an appropriate phosphate binding agent, this product is available at a cost per unit of calcium equivalent to that of an existing preparation.